Home›Clinical trials›A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Enrolling now · NCT07035093

A study testing whether a new weekly shot from Lilly, retatrutide, can help with weight.

What this means for you

Who can join
Adults 18+, have obesity who also have ongoing low back pain, BMI 27+.
What you take
retatrutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.3 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Eli Lilly and CompanyDrug retatrutideClass Triple agonistSites 25 USEnrollment target 586

What this study is for

Primary condition: Obesity. Also studied in: Overweight, Chronic Low Back Pain (CLBP).

Full scientific study title: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have obesity who also have ongoing low back pain, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have a history of axial-predominant low back pain
  • Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
  • Have a body mass index (BMI) >=27 kilograms per square meter (kg/m2) at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Key exclusion criteria

  • Have a non-axial origin low back pain
  • Have had botulinum or steroid injections to the spine within 1 year of screening
  • Have had trigger point injection to the spine within 6 months of screening
  • Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days prior to screening
  • Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening

Where this study is enrolling

This trial has 25 sites across 14 states. Contact a site coordinator directly to start screening.

Arizona2 sites
  • MD First Research - Chandler
    Chandler, Arizona
    480-508-1038
  • Tucson Orthopaedic Institute - North Wyatt Drive
    Tucson, Arizona
    520-404-0276
California4 sites
  • Ark Clinical Research - Fountain Valley
    Fountain Valley, California
    714-988-2021
  • St Joseph Heritage Healthcare
    Fullerton, California
    714-626-8610
  • Clinical Research Institute
    Los Angeles, California
    323-879-9999
  • Artemis Institute for Clinical Research
    San Diego, California
    858-278-3647
Colorado1 site
  • Alpine Clinical Research Center
    Boulder, Colorado
    303-443-7229
Florida6 sites
  • K2 Medical Research - Daytona Beach
    Daytona Beach, Florida
  • Flourish Research - Miami, LLC
    Miami, Florida
    305-631-6704
  • IMA Clinical Research St. Petersburg
    St. Petersburg, Florida
    727-521-9137
  • Care Access - Tampa
    Tampa, Florida
    813-771-5980
  • Charter Research - Lady Lake
    The Villages, Florida
  • Conquest Research
    Winter Park, Florida
    407-916-0060
Kansas1 site
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas
    785-354-9591
Louisiana1 site
  • Care Access - Lake Charles (Bayou Pines)
    Lake Charles, Louisiana
    337-602-6642
Massachusetts1 site
  • MedVadis Research Corporation
    Waltham, Massachusetts
    617-744-1310
Michigan1 site
  • Great Lakes Research Group, Inc.
    Bay City, Michigan
    989-895-9100
Missouri1 site
  • Clinvest Headlands Llc
    Springfield, Missouri
    417-883-7889
North Carolina1 site
  • Center for Clinical Research
    Winston-Salem, North Carolina
Pennsylvania1 site
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania
    814-693-0300
Tennessee1 site
  • New Phase Research and Development
    Knoxville, Tennessee
Texas3 sites
  • FutureSearch Trials of Neurology
    Austin, Texas
    512-380-9925
  • Mercy Family Clinic
    Dallas, Texas
    281-944-3610
  • Houston Research Institute
    Houston, Texas
    281-809-3234
Virginia1 site
  • Sovah Clinical Research-River District
    Danville, Virginia

Timeline

Started enrolling: 2025-05-29. Expected completion: 2027-09. Last updated on ClinicalTrials.gov: 2026-05-20.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.